Pfizer Targets Cancer-Related Weight Loss With New Ponsegromab Study

Pfizer’s RSV Revaccination Trial Targets Durable Booster Revenue in High‑Risk Adults

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

Novo Bets on Next Chapter While Eli Lilly Extends Its GLP-1 Dominance

Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing

C4 Therapeutics Says Cemsidomide-Elranatamab Phase 1b Trial Clears 75 Μg Dose as Safe in Multiple Myeloma

After Capital-Markets Day Flop, Novo Strikes Licensing Deal That Sends a Swedish Company's Stock Soaring

Novo Nordisk Licenses Nanexa Drug Delivery Technology

Moderately bullish activity in Pfizer with shares up 0.9%

Cboe data shows mixed options sentiment in Novo Nordisk with shares up 0.96%

Viking Therapeutics Advances VK2735 Obesity Trial, Keeping VKTX in the Weight Loss Race

Pfizer’s Japanese RSV Vaccine Study Wraps Up, Expanding Adult Market Potential

Novo Nordisk A/S Series B Stock Rises Thursday, Outperforms Market

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Pfizer call volume above normal and directionally bullish

Lilly's Next-Gen Obesity Efforts Could Tip Scales Further in Its Favor, Citi Says

Viking Therapeutics Shares Down 15% After Co Prices Upsized Stock, Convertible Offerings

U.S. Stocks on the MOVE-Everpure, Dropbox, Darden Restaurants